📣 Send us your press release
Site updates every 15 minutes
Science

CataX AI secures 40 million RMB for AI-assisted drug development

Shanghai-based startup CataX AI has raised 40 million RMB in seed funding from Qiming Venture Partners to advance its AI-driven clinical development platform.

16 November 2026
CataX AI secures 40 million RMB for AI-assisted drug development

Shanghai-based CataX AI has raised 40 million RMB in a seed funding round. Qiming Venture Partners, which incubated the startup, served as the sole investor for the round.

The company utilizes an operating model dubbed "Clinical-of-One," which integrates AI agents to assist human specialists in reviewing research, drafting regulatory documents, and processing complex data. The company plans to leverage this technology to license or co-develop drug candidates through preclinical and early clinical stages, aiming to achieve clinical proof of concept more efficiently.

Leadership includes CEO Wang Zilong, who holds a background in clinical medicine and AI research at Microsoft Research Asia, and co-founder Jiang Zhemin, who brings over 15 years of experience in clinical development. CataX AI intends to scale its operations by reusing data and methodologies across different development programs.

Original source: technode.com